

REFERENCES

REFERENCES

Aiken, J.W. and Vane, J.R. (1973) :

Intra renal prostaglandine release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Ther., 184:678-87.

Barbour, B.;Szatkowski, M.; Ingledawn, A. and Attwell D. (1989):

Arachidonic acid induces a prolonged inhibition of glutamate uptake into glial cells. Nature, 342:918-20.

Bennett, P.R.; Elder, M.G. and Myattl, J. (1998):

The effects of lipoxxygenase metabolites of arachidonic acid upon contractility of human pregnant myometrium. Prostaglandins, 33:837-44.

Bevis, P.J.R.; Bird, H.A. and Lapham, G. (1996):

An open study to assess the safety and Tolerability of meloxicam 15mg in subjects with rheumatic disease and mild renal impairment. BR J Rheumatol, 35 (Supp 1): 56-60.

Bjarnason, I.; Hayllar, J.; Parker, J.; Schupp, J. and Macpherson, A. (1994) :

A randomized double blind, cross over comparative endoscopy study on gastroduodenal tolerability of NSAIDs. Gastroenterology, 106(Suppl.4):A 53.

Boss, G.R. and Seegmiller J.E. (1988):

Hyperuricemia and gout: classification, complications, and mangment. N Engl J Med., 200:1459-1468.

Bottcher, I.; Schweizer, A.; Glatt, M. and Werne, H. (1987):

Asulphonamidoindanone CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastrointestinal ulcerogenicity in rats. Drugs Exp Clin Res., 13:237-45.

Boulton, J.M.; Geddes, C.G.; Heinzl, M.; Turck, D.; Nehmiz, G. and Bevis PJR. (1996):

Meloxicam pharmacokinetics in renal impairment. Br. J. Clin. Pharmacol. : in Press.

Bowers G.N. and Mc Comb R.B. (1975):

Measurment of total alkaline phosphatase activity in human serum. Clin. Chem. 21: 12.

Brenner, B.E. and Simon, R.R. (1982):

Management of salicylate intoxication. Drugs, 24:335-340.

Brooks, P.M. and Day, R.O. (1991):

NSAIDs differences and similarities. N Engl J Med, 324:1716-1725.

Busch, U.; Heinzl, G. and Nehmiz, G.(1996):

Interaction of cimetidine, malox or aspirin. J.Clin.Pharmacol.,36:79-84.

Busch, U.; Heinzl, G. and Narjes, H. (1997):

Pharmacokinetics of meloxicam in patients with hepatic cirrhosis in comparison with healthy volunteers. Clin Drug Invest., 11(2):97-107.

Chan, C.; Boyce, S.and Brideau, C. (1995):

Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel NSAID with an ulcerogenic sparing effect in rat and non human primate stomach. J Pharmacol Exp Ther., 274:1531-7.

Clark, R.A.F. and Henson, P.M. (1988):

The Molecular and Cellular Biology of Wound Repair. Plenum Press, New York.

Copland, R.A.; Williams, J.M. and Giannarasj R.S. (1994) :

Mechanism of selective inhibition of the inducible isoform of prostaglandin. Proc. NatL. Acad. Sci. U.S.A., 91 : 11202-6.

Davles, P. ;Bailey, P.J.; Goldenberg, M.M.; and Ford, A.W. (1984) :

The role of arachidonic acid in oxygenation products in pain and inflammation. Annu Rev Immunol.,:335-57.

De Gaetano, G.; Cerletti, C.; Dejana, E. and Latini, R. (1985) :

Pharmacology of platelet inhibition in humans . Circulation ,72:1185-93.

Degner, F.; Heinzl, G. and Turck, D. (1995):

The effect of meloxicam on the pharmacokinetics of B-acetyldigoxin. Br. J. Clin. Pharmacol., 40: 486-488.

DeWitt, D. (1991) :

Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Blochim. Blophys. Res. Commun. 164:1358-65.

Drury R.A.B. and Wallington E.A.(1980)

Carleton's histological techniques. Fifth edition, Oxford university press, London, New York, Toronto.

Engelhardt, G.; Homma, D.; Schlegel, K.; Schnitzler, C.H.R. and Utzmann, R. (1996):

General pharmacology of meloxicam. Part. I Gen Pharmacol.,27:673-77.

Engelhardt, G.; Bogel, R.; Schinitzler, C. and Utzman R. (1995) :

Meloxicam Influence on arachidonic acid metabolism. Part 1 In vitro findings. Biochem Pharmacol., 3:109-17.

Ferreira, S.H. (1972):

Prostaglandins aspirin like drugs and analgesia. Nature., 240:200-3.

Fries, J.F.; Williams, C.A.; Ramey, D. and Bloch D.A. (1993) :

The relative toxicity of disease modifying anti rheumatic drugs. Arthritis Rheum. ,36:2657-306.

Furchgott, R.F. and Bhadrakou, S. (1953)

Reaction of strips of rabbit aorta to epinephrin Isopyl arterenol, sodium Nitrate and other drugs. J. pharmacol. Exp. Thes. 108:129-143.

Futaki, N.; Arai, I.; Humasaka, Y.; Takahashi, S.; Higuchi, S. and Otomo, S. (1993):

Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol. 45:753-5.

Gans, K.R.; Galbraith, L. and Romman, R.J. (1990):

Anti-inflammatory and safety profile of DuP697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther., 254:180-7.

Gierse, J.K.; Hauser, S.D.; Creely, D.P.; Koboldt, C.; Rhangwala, S.H. and Isatson, P.C. (1995):

Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J., 305:479—84.

Goppelt, W. and Struebe, M. (1995):

Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) Isozyme expression. Prostaglandins leukotrienes Essential Fatty acids, 52: 213-22.

Hart, F.D. and Huskisson, E.C. (1988):

NSAIDs current status and rational therapeutic use.
Drugs, 27:232.

Hemler, M.; Lands, W. and Smith, W.L. (1976):

Purification of the Cyclo-oxygenase isoforms. J.
Biochem., 251 : 2575-9.

Herbette, L.; Vecchiarelli, J. and Trummlitz, G. (1996):

NSAIDs mechanism of action: The role of
intracellular pharmacokinetics. In: Vane, J.; Botting, J. and
Botting, R. (1996) : Improved non steroidal anti
inflammatory drug -Cox-2 enzyme inhibitors, London,
Kluwer Academic Publishers: 85-102.

Herschmann, H.R. (1994):

Regulation of prostaglandin synthase-1 and prostaglandin
synthase-2. Cancer Metastasis rev., 13:241-56.

International federation of clinical chemistry (1980):

Scientific Committee. J. Clin. Chem. & Clin. Biochem.
18:521 - 534.

Isekis, I., Bogel, R. and Schnitzler, C. (1995):

Differential inhibition of prostaglandin endoperoxide synthase isoenzymes by asprine and other NSAIDs, J. Biol. Chem., 268: 6610 – 4.

Hubener, G.; Sander, O.; Degner, F. and Rqu ,R. (1994) :

Lack of pharmacokinetic interaction of meloxicam with methotrexate in RA patients. Scand. J. Reumatol., Suppl. 98: Abstact 108.

Jaffe, E.A. and Weksler, B.B.(1997) :

Recovery of endothelial cell prostacyclin production after low dose aspirin. J. Clin. Invest., 63 : 352-535.

Konteurk, R.I.; Kahan, A.M. and Hawkey C.R. (1998):

Improvement in the gastrointestinal tolerability of selective COX-2 inhibitor Meloxicame. Br. J. Rheum.,37: 946 – 95.

Langman, M.J.S.; Well, J. and Wainwright, P. (1994) :

Risks of bleeding peptic ulcer associated with individual NSAIDs. Lancet, 343:1075-8.

Lee, P.(1973):

The evaluation of a functional index in rheumatoid arthritis. Scand. J. RhemnatoL., 2 : 71-77.

Lehmann, H.A.; Baumeister, M.; Lutzen, L. and Wiegler, J. (1996):

Meloxicam toxicological Overview. Inflammopharmacology, 42: 105-12

Lemmel, E.M.; Bottenw, R.; and Vargas, R. (1996):

A double blind, Randomized placebo controlled trial to evaluate the efficacy and safety of meloxicam, a new NSAID, in daily doses of 7.5-10 mg once daily on man with rheumatoid arthritis. J. Rheumatol., in press.

Linden, B.; Distel, M. and Bluhmke K (1996):

A double blind study compare to the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteo arthritis of the hip. Br. J. Rheumat, 35 (supp 7): 35-38.

Luger, P.; Daneck, K.; Engel, W.; Trummlitz, G. and Wagner K (1996):

Structure and physicochemical properties of meloxicam, a new NSAID. Eur. J. Pharm. Sci., 4:175 – 187.

Marcus, A.; Brookman G. and Safier, M.L. (1982):

Formation of leukotriens and other hydroxy acids during platelet-neutrophil interactions in vitro. Biochim. Biophys. Res. Comm., 109:130-137.

Meade, E.A.; Smith, W.L. and DeWitt, D.L. (1993):

Differential inhibition of COX isoenzymes by aspirin and other NSAIDs. J. Biol. Chem., 268:6610-6614.

Mene, P. and Dunn, M.J. (1986):

Contractile effects of TXA₂ and endoperoxide analogues on cultured rat glomerular mesangial cells. Am. J. Physiol. 251:F1092-F1035.

Mitchell, J.A.; Akarasereenont, P.; Thiemermann, C.; Flower, R.J. and Vane, J.R. (1994):

Selectivity of nonsteroidal anti inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA. 11693-7.

Moncada, S. and Vane, J.R. (1979):

Pharmacology and endogenous roles of Prostaglandin endoperoxides, thromboxane A₂ and prostacyclin. Pharmacol Rev., 30:293-331.

Morrison, A.R. (1986):

Biochemistry and Pharmacology of renal arachidonic acid metabolism. Am. J. Med., (Suppl 1A) :3-11.

Muller, F.O.; Schall, R. and Devall, A.C.(1995):

No interaction of meloxicam with either single or multiple repeated doses of furosemide. Eur. J. Clin. Pharmacol., 48:247-251.

Narjes, H.; Turck, D.; Busch, U.; Heinzel, G. and Nehmiz, G. (1996):

Pharmacokinetics and tolerability of meloxicam after I.m. administration. Br. J. Rheumatol., 41:435-139.

Nathan, C.F. (1987):

Secretory products of macrophages, Leuckocyte adhesion to endothelium in inflammation. Journal of clinical Investigation, 79: 319-26.

Needleman, P. (1994):

In search of a better NSAID. Drugs Exp. Clin. Res., 15:501-9.

Otto, j.; Dewitt, D. and Smith, W. (1993):

N-glycosylation of Prostaglandin endoperoxide synthase-1 and 2 and their orientation in the endoplasmic reticulum. J. Biol. Chem., 268:18234-42.

Paget, G.T. and Barnet J.M.(1964):

In evaluation of drug activities pharmacometrics.

Eds. Laurence D.R. and Bacharach A.L.;1 – 135.

Academic press London and New York.

Pairat, M. and Engelhardt, G. (1996):

*Distinct isoforms (COX-1 and COX2) of cyclooxygenase:
possible physiological and therapeutic implications.
Clinical Pharmacol., 10: 1-15.*

Paller, W.I. ;Bevis, P.J.(1996):

*Non steroidal anti inflammatory drugs, side effects and
tolerability. Clinic Therap 18(7);226-235.*

Patoia, L.; Santucci, L. and Furno, P. (1995):

*Comparison of gastro intestinal tolerability of meloxicam,
piroxicam and placebo by fecal blood loss, endoscopy and
symptom evaluation. Rheumatol. Eur., 24 Suppl.3: E258.*

Patton C.J. and Croach S.R.(1977):

Anal. Chem. 49 : 464 – 469.

Picot, D.; Loll, P.J. and Gravaite, R.M. (1994):

*The x-ray crystal structure of the membrane protein
prostaglandin H2 Synthase-1. Nature., 367:243-9.*

Premack, B.A. and Schall, T.J.(1996):

Chemokine receptors: gate ways to inflammation and infection. Nat. Med., 2:1174,1996.

Prouse, P.J.; Bevis, P.J.; Bluhmkie, A. and Distel, M. (1996):

Evaluation of the Safety, tolerability. and efficacy of meloxicam tablets in patients with oesteo arthritis. Clin. Ther.,18 (3); 429-439.

Reitz, D.B.; Li, J.j. and Norton, M.B. (1994):

Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopantenes are potent and orally active COX-2 inhibitors. J. Med. Chem., 37:3878-81.

Rosen, G.D.; Birkenmeier, T.M.; Raz, A. and Holtzman, M.T. (1989):

Idenfication of a cyclooxygenuse related gene and its potential role in PG formation. Biochem. Bioph. Res. Commun.,164:1358-65.

Sander, O.; Hubner, G.; Turck, D.; Degner, F. and Rau, R.(1995):

Meloxicam pharmacokinetics in elderly compared to younger male and female patlents with rheumatoid arthritis (RA). Rheumatol. Eur., 3:221 Abstract NO:D18.

Sandler, D.P.; Burr, F.R. and Weinberg, C.R. (1990):

Non steroidal anti-inflammatory drugs the risk for chronic Renal disease. Intern. Med.,115:165-72.

Schmid, J.; Busch, U. and Trummlitz, G. (1995)

Meloxicame: metabolic profile and bio transformation products in rat. Xenobiotica, 25:1219-1236.

Serhan, C.N. (1994).

Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta., 1212:1

Shen, T.Y. (1979):

Prostaglandins synthase inhibitors. In Vane JR, Ferreira SH, editors. Anti-inflammatory drugs. Berlin, Springer-Verlag: 305-47.

Simmons, D.L.; Chipman, J.G. and Evett, J.G. (1991):

Multiple cyclooxygenases: cloning of a mitogen inducible form, Prostaglands, leukotrienes, lipoxins. New York: Plenum Press, :67-77.

Sirois, J.; Simmons, D.L. and Richard, J.S. (1992):

Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide synthase in rat preovulatory follicles : induction in vivo and in vitro. J. Biol. Chem., 267:11586-92.

Smilkstein, J.G.; Knapp, G.L.; Kulig, K.W. and Rumack, B.H. (1988):

Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. N. Engl. J. Med. 319:1557-1562.

Smith, W.L. and Marnett, L.J. (1994):

Prostaglandin endoperoxide synthase. In biologic systems. New York,:163-99.

Sporn, M.B. and Roberts, A.B. (1997):

Peptide growth factors and inflammation, tissue repair and cancer. Journal of clinical investigation 78, 329-32.

Sraer, J.; Rigaud, M. and Bens, M. (1983):

Metabolism of Arachidonic acid via the Lipoxigenase pathway in human and murine glomeruli. J. Biolchem., 258:4328.

Tagari, P.; panneton, M. and Rasori, R. (1994):

Assessment of NSAID: Gastroentropathy in primates.
Can. J. Physiol. Pharmacol., 72 (Suppl 1) : 267.

Turck, D. and Busch, U. (1996):

A review of clinical pharmacokinetics of meloxicam. *Br. J. Rheumatol.* 35(suppl 1) :13-16.

Turk, D.; Capf, S.U. and Heinzl, G. (1998):

Lack of interaction between meloxicam and warfarin in healthy volunteers. *Eur. J. Clin. Pharmacol.*, 20: 57-70.

Vane, J.R.; Mitchell, J.A. and Appleton, I. (1994):

Inducible isoforms of cyclooxygenase and nitric oxide synthase in in inflammation. *Proc. Natl. Acad. Sci. U.S.A.*, 91 : 2046-50.

Vane, J.R. (1996):

Introduction to mechanism of action of NSAIDs *Br. J. Rheumatol.* 35 (Supp 1) : 1-3.

Vane, J.R. (1971):

Inducible isoforms of cyclooxygenase enzyme. *Br. J. Rheumatol.* 10 : 1-5.

Walker, L.A. and Frolich, J.C. (1987):

*Renal Prostaglandins and leucotrienes. Rev. Physiol.
Biochem. Pharmacol. 107: 1-72.*

Xie, W.; Chipman, J.; Robertson, D.L.; Erikson, R.L. and Simmons,
D.L. (1991):

*Expression of a mitogen responsive gene encoding
prostaglandin synthase is regulated by mRNA splicing.
Proc. Natl. Acad. Sci. U.S.A. 88:2692-6.*